000154585 001__ 154585
000154585 005__ 20240229123107.0
000154585 0247_ $$2doi$$a10.3389/fbioe.2020.00179
000154585 0247_ $$2pmid$$apmid:32211398
000154585 0247_ $$2pmc$$apmc:PMC7067901
000154585 0247_ $$2altmetric$$aaltmetric:77138470
000154585 037__ $$aDKFZ-2020-00864
000154585 041__ $$aeng
000154585 082__ $$a570
000154585 1001_ $$0P:(DE-He78)43b43c5f20ed70299251a446ad8ec973$$aSrivastava, Aayushi$$b0$$eFirst author
000154585 245__ $$aIdentification of Familial Hodgkin Lymphoma Predisposing Genes Using Whole Genome Sequencing.
000154585 260__ $$aLausanne$$bFrontiers Media$$c2020
000154585 3367_ $$2DRIVER$$aarticle
000154585 3367_ $$2DataCite$$aOutput Types/Journal article
000154585 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1683888645_20082
000154585 3367_ $$2BibTeX$$aARTICLE
000154585 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000154585 3367_ $$00$$2EndNote$$aJournal Article
000154585 500__ $$a#EA:B062#EA:C050##LA:C050#LA:B062#
000154585 520__ $$aHodgkin lymphoma (HL) is a lymphoproliferative malignancy of B-cell origin that accounts for 10% of all lymphomas. Despite evidence suggesting strong familial clustering of HL, there is no clear understanding of the contribution of genes predisposing to HL. In this study, whole genome sequencing (WGS) was performed on 7 affected and 9 unaffected family members from three HL-prone families and variants were prioritized using our Familial Cancer Variant Prioritization Pipeline (FCVPPv2). WGS identified a total of 98,564, 170,550, and 113,654 variants which were reduced by pedigree-based filtering to 18,158, 465, and 26,465 in families I, II, and III, respectively. In addition to variants affecting amino acid sequences, variants in promoters, enhancers, transcription factors binding sites, and microRNA seed sequences were identified from upstream, downstream, 5' and 3' untranslated regions. A panel of 565 cancer predisposing and other cancer-related genes and of 2,383 potential candidate HL genes were also screened in these families to aid further prioritization. Pathway analysis of segregating genes with Combined Annotation Dependent Depletion Tool (CADD) scores >20 was performed using Ingenuity Pathway Analysis software which implicated several candidate genes in pathways involved in B-cell activation and proliferation and in the network of 'Cancer, Hematological disease and Immunological Disease.' We used the FCVPPv2 for further in silico analyses and prioritized 45 coding and 79 non-coding variants from the three families. Further literature-based analysis allowed us to constrict this list to one rare germline variant each in families I and II and two in family III. Functional studies were conducted on the candidate from family I in a previous study, resulting in the identification and functional validation of a novel heterozygous missense variant in the tumor suppressor gene DICER1 as potential HL predisposition factor. We aim to identify the individual genes responsible for predisposition in the remaining two families and will functionally validate these in further studies.
000154585 536__ $$0G:(DE-HGF)POF3-312$$a312 - Functional and structural genomics (POF3-312)$$cPOF3-312$$fPOF III$$x0
000154585 588__ $$aDataset connected to CrossRef, PubMed,
000154585 7001_ $$0P:(DE-He78)f18e077aae13edd9d0d8b911cfcd8e0f$$aGiangiobbe, Sara$$b1$$eFirst author
000154585 7001_ $$0P:(DE-He78)da09d83faa85c143d15611698f7b1eac$$aKumar, Abhishek$$b2
000154585 7001_ $$0P:(DE-He78)4a8b73f9f05542860120bb0e19527fd2$$aParamasivam, Nagarajan$$b3
000154585 7001_ $$aDymerska, Dagmara$$b4
000154585 7001_ $$aBehnisch, Wolfgang$$b5
000154585 7001_ $$aWitzens-Harig, Mathias$$b6
000154585 7001_ $$aLubinski, Jan$$b7
000154585 7001_ $$0P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865$$aHemminki, Kari$$b8
000154585 7001_ $$0P:(DE-He78)f26164c08f2f14abcf31e52e13ee3696$$aFörsti, Asta$$b9
000154585 7001_ $$0P:(DE-He78)b11ccde1801d45d32a6a60f7b396d7dc$$aBandapalli, Obul Reddy$$b10$$eLast author
000154585 773__ $$0PERI:(DE-600)2719493-0$$a10.3389/fbioe.2020.00179$$gVol. 8, p. 179$$p179$$tFrontiers in Bioengineering and Biotechnology$$v8$$x2296-4185$$y2020
000154585 909CO $$ooai:inrepo02.dkfz.de:154585$$pVDB
000154585 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)43b43c5f20ed70299251a446ad8ec973$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000154585 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f18e077aae13edd9d0d8b911cfcd8e0f$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000154585 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)da09d83faa85c143d15611698f7b1eac$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000154585 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4a8b73f9f05542860120bb0e19527fd2$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000154585 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000154585 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f26164c08f2f14abcf31e52e13ee3696$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000154585 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b11ccde1801d45d32a6a60f7b396d7dc$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000154585 9131_ $$0G:(DE-HGF)POF3-312$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunctional and structural genomics$$x0
000154585 9141_ $$y2020
000154585 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000154585 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000154585 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000154585 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central
000154585 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal
000154585 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ
000154585 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review
000154585 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ
000154585 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000154585 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000154585 9202_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x0
000154585 9201_ $$0I:(DE-He78)C050-20160331$$kC050$$lMolekular-Genetische Epidemiologie$$x0
000154585 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x1
000154585 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x2
000154585 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x3
000154585 9200_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x0
000154585 980__ $$ajournal
000154585 980__ $$aVDB
000154585 980__ $$aI:(DE-He78)C050-20160331
000154585 980__ $$aI:(DE-He78)B062-20160331
000154585 980__ $$aI:(DE-He78)HD01-20160331
000154585 980__ $$aI:(DE-He78)C020-20160331
000154585 980__ $$aUNRESTRICTED